A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Duvelisib
DRUG: Gemcitabine
DRUG: Bendamustine

Sponsor

SecuraBio